echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Acta Haematol: Unique mechanism of IgM antibody-mediated acquired von Willebrand syndrome and successful treatment of recombinant von Willebrand factor in one patient

    Acta Haematol: Unique mechanism of IgM antibody-mediated acquired von Willebrand syndrome and successful treatment of recombinant von Willebrand factor in one patient

    • Last Update: 2022-05-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Acquired von Willebrand syndrome (AVWS) is a rare coagulation disorder that may be associated with IgM paraproteinemia


    Vascular Recently, recombinant von Willebrand factor (rVWF) has been used to treat bleeding in patients with hereditary von Willebrand disease, but experience in patients with AVWS is limited


    Patient 1 was an 80-year-old man with recurrent severe transurethral bleeding with a hemoglobin level of 6.


    Table 1: Patient characteristics and laboratory results at presentation

    Table 1: Patient characteristics and laboratory results at presentation Table 1: Patient characteristics and laboratory results at presentation
    Figure


    Figure 1: Multimer analysis of patient plasma at presentation


    But the transurethral bleeding did not resolve The transurethral bleeding stopped and did not recur

    Immediately thereafter, immunosuppressive therapy with prednisolone and rituximab was started, but VWF activity did not improve and bleeding remained non-resolved


    2

    Patient 2 was a 71-year-old man who presented with epistaxis and severe intestinal bleeding after colon polyps removal, requiring transfusion of red blood cell concentrates


    Patient 2 was a 71-year-old man who presented with epistaxis and severe intestinal bleeding after colon polyps removal, requiring transfusion of red blood cell concentrates


    The research team believes that it is safe to use rVWF and VWF-specific IgM antibodies to fully increase VWF activity and stop bleeding


    Original source:

    Original source:

    Höpting M, Budde U, Tiede A, Grube M, Hahn J, Herr W, Heimerl S, Hart C.


    Höpting M, Budde U, Tiede A, Grube M, Hahn J, Herr W, Heimerl S, Hart C.




    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.